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Abstract
Clinical isolates of Escherichia coli with reduced susceptibility to oxyimino-cephalosporins and not susceptible to clavulanic acid syn-
ergy (n = 402), collected from Norwegian diagnostic laboratories in 2003–2007, were examined for the presence of plasmid-medi-
ated AmpC b-lactamases (PABLs). Antimicrobial susceptibility testing was performed for b-lactam and non-b-lactam antibiotics using
Etest and Vitek2, respectively. The AmpC phenotype was conﬁrmed using the boronic acid test. PABL-producing isolates were
detected using ampC multiplex-PCR and examined by blaAmpC sequencing, characterization of the blaAmpC genetic environment,
phylogenetic grouping, XbaI- pulsed-ﬁeld gel electrophoresis (PFGE), multi-locus sequence typed (MLST), plasmid proﬁling and
PCR-based replicon typing. For the PABL-positive isolates (n = 38), carrying blaCMY-2 (n = 35), blaCMY-7 (n = 1) and blaDHA-1 (n = 2),
from out- (n = 23) and in-patients (n = 15), moderate-high MICs of b-lactams, except cefepime and carbapenems, were determined.
All isolates were resistant to trimethoprim-sulphamethoxazole. Multidrug resistance was detected in 58% of the isolates. The genes
blaCMY-2 and blaCMY-7 were linked to ISEcp1 upstream in 32 cases and in one case, respectively, and blaDHA-1 was linked to qacED1-
sul1 upstream and downstream in one case. Twenty isolates were of phylogenetic groups B2 or D. Thirty-three XbaI-PFGE types,
including three clusters, were observed. Twenty-ﬁve sequence types (ST) were identiﬁed, of which ST complexes (STC) 38 (n = 7),
STC 448 (n = 5) and ST131 (n = 4) were dominant. Plasmid proﬁling revealed 1–4 plasmids (50–250 kb) per isolate and 11 different
replicons in 37/38 isolates; blaCMY-2 was carried on transferable multiple-replicon plasmids, predominantly of Inc groups I1 (n = 12),
FII (n = 10) and A/C (n = 7). Chromosomal integration was observed for blaCMY-2 in ten strains. CMY-2 is the dominant PABL type
in Norway and is associated with ISEcp1 and transferable, multiple-replicon IncI1, IncA/C, or IncFII plasmids in nationwide strains of
STC 448, STC 38 and ST131.
Keywords: CMY-2, IncI1, plasmid-mediated AmpC-b-lactamases, ST131, ST38
Original Submission: 20 November 2008; Revised Submission: 3 February 2009; Accepted: 21 February 2009
Editor: R. Canton
Article published online: 22 June 2009
Clin Microbiol Infect 2010; 16: 171–178
Corresponding author and reprint requests: U. Naseer
and A. Sundsfjord, Reference Centre for Detection of Antimicrobial
Resistance (K-res), Department of Microbiology and Infection
Control, University Hospital of North-Norway, N-9038 Tromsø,
Norway
E-mail: Umaer.Naseer@uit.no; Arnﬁnn.Sundsfjord@fa.uit.no
Introduction
Plasmid-mediated AmpC b-lactamases (PABLs) have been
reported worldwide in various Gram-negative bacteria since
their ﬁrst description in 1989–90 [1]. PABLs are clinically
important because they confer transferable resistance to all
b-lactams except fourth-generation cephalosporins and
carbapenems. In combination with loss of outer membrane
porins, they may also mediate resistance to carbapenems [2].
The occurrence of most PABLs appears to be sporadic, but
nosocomial outbreaks caused by Klebsiella pneumoniae and
Escherichia coli have also been reported [3,4].
PABLs have descended from chromosomal ampC genes of
different bacteria, e.g. blaCMY from Citrobacter freundii and
Aeromonas spp. and blaDHA from Morganella morganii [1].
Capture and mobilization of blaCMY from the chromosomes
of C. freundii and Aeromonas spp. to plasmids is thought to
have been mediated by ISEcp1 and class 1 integron-bearing
ISCR1 elements [5,6], subsequently spreading to new hosts
by transferable IncA/C and IncI1 plasmids [7]. Similarly, the
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DHA enzymes have also been linked to class 1 integrons-
bearing ISCR1 upstream [8]. DHA enzymes are the only
inducible PABLs with a functional ampR regulator gene [8].
Association of blaDHA with IncFII type plasmids has so far
only been documented in a single study [7].
Escherichia coli contains a non-inducible chromosomal
ampC gene, and phenotypic tests do not distinguish between
over-expression of the intrinsic ampC and the presence of
PABL. Thus, the prevalence of PABLs in E. coli is unknown as
a result of the lack of detailed molecular characterization
and population analysis of PABL-producing E. coli. Our recent
study on selected Norwegian E. coli strains (from 2003–
2005) with an AmpC-phenotype revealed the presence of
strains over-expressing the chromosomal ampC gene as well
as CMY-producing strains [9]. A single study from France
linked CMY-2 expressing strains to phylogenetic group B1
[10]. The aim of this study was to describe the molecular
epidemiology of the Norwegian PABL-producing E. coli
strains from 2003–2007.
Materials and Methods
Strains and antimicrobial susceptibility
From March 2003 to December 2007, the Norwegian
Reference Centre for Detection of Antimicrobial Resistance
(K-res) received 402 clinical isolates of E. coli with reduced
susceptibility to oxyimino-cephalosporins without clavulanic
acid synergy from 21 nationwide diagnostic laboratories. Ini-
tial antimicrobial susceptibility testing was performed in each
laboratory by routine methods interpreted according to the
‘Norwegian Working Group on Antibiotics‘ guidelines and
EUCAST breakpoints. Isolates were examined at K-res using
b-lactam Etests (AB Biodisk, Solna, Sweden) according to the
manufacturer¢s instructions for: ampicillin, amoxicillin-clavul-
anic acid, piperacillin, piperacillin-tazobactam, cefuroxime,
cefoxitin, cefpodoxime, cefotaxime, ceftazidime, cefepime,
aztreonam, imipenem and meropenem. Bacterial identiﬁca-
tion was performed using the Vitek2 ID-GNB system (bio-
Me´rieux, Marcy l’E´toile, France) or API ID32E (bioMe´rieux).
Vitek2 ASTN023 (bioMe´rieux) was used to determine
susceptibility to non-b-lactam antibiotics: nitrofurantoin, gen-
tamycin, tobramycin, ciproﬂoxacin and trimethoprime-sulfa-
methoxazole. Multidrug resistance was deﬁned as resistance
to ‡2 non-b-lactam antibiotics. Synergy tests were
performed by ESBL Etests (AB Biodisk) including cefotaxime,
ceftazidime and cefepime with clavulanic acid. Phenotypic
tests for AmpC b-lactamases were performed using boronic
acid with cefoxitin [11]. Selection criteria for analysis of plas-
mid-mediated ampC-genes were: (i) reduced susceptibility to
third-generation cephalosporins (cefotaxime and ceftazidime
MICs >1 mg/L) without clavulanic acid synergy, and (ii)
positive boronic acid inhibition test. A total of 276 strains
fulﬁlled these criteria.
Detection of bla genes
Isolates were screened for the presence of plasmid-mediated
ampC genes using multiplex PCR covering the six families of
blaAmpC-genes (blaACC, blaCIT, blaDHA, blaEBC, blaFOX and
blaMOX) [12], and PCR for blaCTX-M [13]. Amplicons were
conﬁrmed by bi-directional sequencing.
Genetic environment of blaAmpC-alleles
Association between ISEcp1 and blaCMY was examined by
ISEcp1-blaCMY linkage PCR [9], and between blaDHA and the
3¢CS region of a probable class 1 integron upstream and
downstream by PCR [14].
Population structure analysis
All isolates were classiﬁed according to E. coli phylogenetic
groups A, B1, B2 and D using multiplex PCR [15],
XbaI-pulsed-ﬁeld gel electrophoresis (PFGE) typed [16], and
multi-locus sequence typed (MLST) according to the scheme
developed by Achtman (http://web.mpiib-berlin.mpg.de) [17].
Puriﬁed PCR products were sent to Macrogen (Seoul,
Korea) for DNA sequencing. Sequence alignment was per-
formed using BioEdit sequence Alignment Editor [18] and
BURST (Based Upon Related Sequence Types) analysis on
allelic proﬁles online (http://linux.mlst.net/burst.htm).
Plasmid analysis
Plasmids were typed with PCR-based replicon typing (PBRT)
[19]. S1-nuclease (Promega, Madison, USA) digested plasmid
DNA was examined by PFGE [9,20], blotted onto positively
charged nylon membranes (Roche Diagnostics GmbH, Mann-
heim, Germany) using the VacuGene XL Vacuum Blotting
System (Amersham and Bioscience, Oslo, Norway) for trans-
fer, and hybridized (68C, 20 h) with probes of the blaCMY-2
gene and replicon FII, A/C and I1 (PCR DIG Probe Synthesis
Kit, Roche Diagnostics).
Transferability of blaCMY
Randomly selected isolates (n = 10) were analysed for the
ability to transfer blaCMY to rifampicin-resistant, plasmid free
E. coli (J53-2). Conjugation was performed using blaCMY plas-
mids of both IncI1 and IncA/C types. Transconjugants were
selected on Luria–Bertani plates containing cefotaxime (2 lg/
ml) and rifampicin (100 lg/ml), conﬁrmed by XbaI-PFGE,
S1-nuclease-PFGE and antimicrobial susceptibility to nalidixic
acid, cefotaxime, gentamycin, ciproﬂoxacin and trimetho-
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prime-sulfamethoxazole by disc diffusion (Oxoid, Basing-
stoke, UK).
Results
Bacterial strains
A total of 38 (14%) out of 276 E. coli isolates were positive
for plasmid-mediated ampC-genes using multiplex-PCR.
These strains were obtained from 13 nationwide laborato-
ries, isolated from urine (n = 32), blood (n = 4), skin (n = 1)
and abscess (n = 1) samples from in- (n = 15) and out-
patients (n = 23). Results from individual isolates are summa-
rized in Table 1.
Antimicrobial susceptibility
The minimum inhibitory concentration (MIC) means and
ranges for piperacillin, piperacillin-tazobactam, oxyimino-
cephalosporins, cefoxitin, cefepime and aztreonam within the
different PABL types are presented in Table 2. All PABL-pro-
ducing strains expressed moderate to high MIC levels for all
substrates except cefepime. In all strains, MIC values were
higher for cefuroxime and cefpodoxime than cefotaxime or
ceftazidime. Co-resistance was seen for trimethoprime-sulfa-
methoxazole (n = 38; 100%), aminoglycosides gentamycin
and/or tobramycin (n = 15; 40%), ciproﬂoxacin (n = 14; 37%)
and nitrofurantoin (n = 12; 32%), with multidrug resistance
observed in 23 (58%) strains (Table 1).
Characterization of PABLs and the genetic environment
PABL types identiﬁed were: blaCMY-2 (n = 35; 92%), blaCMY-7
(n = 1; 3%) and blaDHA-1 (n = 2; 5%). Thirty-two (91%) of
blaCMY-2 and the single blaCMY-7 were linked to the ISEcp1
element upstream. A single blaDHA-1 was linked to the 3¢CS
region of a class 1 integron upstream and downstream as
previously observed [6,8] (Table 1).
Phylogenetic classiﬁcation
Isolates were distributed into potentially virulent phyloge-
netic groups B2 (n = 7; 18%) and D (n = 13; 34%) associated
with extraintestinal infections, and groups A (n = 12; 32%)
and B1 (n = 6; 16%) of commensal strains and strains associ-
ated with enterotoxigenic and enterohaemorrhagic infec-
tions.
XbaI-PFGE
A total of 33 different PFGE-types were detected among 37
typeable strains, (DNA from a single isolate autodigested,
K26-21), including 30 single types and three clusters (>90%
similarity) containing two to three isolates each (C1-C3).
Clustered isolates were geographically related and of identi-
cal phylogenetic grouping in C1 and C3 (Fig. 1).
MLST
MLST analysis identiﬁed 25 different STs, including ﬁve novel
STs (ST963, ST976, ST977, ST979 and ST981). A total of 29
isolates were related to 14 previously described ST-
complexes (STCs) dominated by 38 (n = 7, 18%) and 448
(n = 5, 13%). Furthermore four isolates were sequence
typed as ST131 (11%). Strains within these STs were distrib-
uted nationwide, isolated in different periods and included
isolates showing diverse PFGE proﬁles (Table 1).
Isolates related to STC 38 included one isolate of ST38,
four single locus variant (SLV) isolates of ST778, one double
locus variant (DLV) isolate of ST963 and one SLV isolate
ST981 of ST963. All isolates related to STC 38 were CMY-2
producers, grouped into phylogenetic group D and included
PFGE C3 (ST778). Isolates related to STC 448 were of
ST448, CMY-2 producers and of phylogenetic groups B1
(n = 3) and A (n = 2), including PFGE C2. Isolates related to
ST131 were all of phylogenetic group B2 (Fig. 1).
Plasmid analysis
S1-nuclease plasmid proﬁles were obtained for 36/38 (95%)
isolates. DNA from a single isolate autodigested (K26-21)
and no plasmids bands were observed for one isolate (K36-
28). A total of 1–4 plasmids ranging from 50 to 250 kb were
observed per strain. A total of ten single plasmid and 26
multiple plasmid isolates were identiﬁed.
PBRT identiﬁed 11 different replicons in 37/38 isolates;
FII (n = 33; 89%), FIB (n = 33; 89%), I1 (n = 17; 46%), Y
(n = 17; 46%), FIA (n = 15; 41%), A/C (n = 11; 27%), K
(n = 5; 14%), P (n = 4; 11%), N (n = 2; 5%), B/O (n = 2;
5%) and L/M (n = 1; 3%). None of the 18 replicons
screened for were detected in the isolate (K36-28) that
showed no plasmids.
Hybridization with the blaCMY-2 probe identiﬁed a plasmid
location in 25/35 CMY-producing isolates. In the remaining
10/35 isolates, the probe hybridized with a fragment
>582 kb, consistent with a possible chromosomal location
(data not shown). Chromosomally associated blaCMY were all
linked to ISEcp1 upstream, suggesting a possible transposition
event. When hybridized on plasmids, blaCMY was observed in
ﬁve single- and 20 multiple-plasmid isolates. Single-plasmid
isolates (n = 5) were positive for six replicon types by PCR,
indicating up to ﬁve replicon types co-located on the same
plasmid: I1 (n = 2), I1-A/C-FII-FIB-Y (n = 1), I1-FII-FIB-N
(n = 1) and A/C-FII-FIB (n = 1). Alternatively, the multiple-
replicon ﬁnding may represent plasmids undetected by the
S1-nuclease method or chromosomally integrated plasmid
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TABLE 2. MIC means and ranges for selected b-lactam antibiotics including PIP, PTZ, CXM, CPD, CTX, CAZ, FOX, FEP and
ATM in relation to PABL types in E. colia
Bla (n)
MIC (mg/L)b
PIPa PTZa FOXa CXMa CPDa CTXa CAZa FEPac ATMa
Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range
BlaAmpC (38) 232 24–>256 24 2–192 >256 48–>256 185 32–>256 >256 48–>256 49 6–>256 122 12–>256 0.86 0.5–4 18 2–96
BlaCMY-2 (35) >256 24–>256 28 2–192 >256 48–>256 196 32–>256 >256 128–>256 56 6–>256 140 12–>256 0.96 <0.25–4 20 2–96
BlaCMY-7 (1) 96 96 8 8 192 192 >256 >256 >256 >256 32 32 48 48 0.75 0.75 8 8
BlaDHA-1 (2) 96 64–128 8 4–12 >256 192–>256 112 96–128 152 48–>256 10 8–12 18 12–24 0.44 <0.25–0.75 8 4–12
aPIP, piperacillin; PTZ, piperacillin-tazobactam; FOX, cefoxitin; CXM, cefuroxime; CPD, cefpodoxime; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam.
bThe value 512 mg/L has been used to calculate the mean for strains displaying a MIC of >256 mg/L.
cThe value 0.125 mg/L has been used to calculate the mean for strains displaying a MIC of <0.25 mg/L.
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FIG. 1. Dendrogram to illustrate the genetic relatedness of 37 out of 38 plasmid-mediated AmpC b-lactamase (PABL)-producing Norwegian Esc-
herichia coli isolates examined by pulsed-ﬁeld gel electrophoresis (PFGE). The reference number, hospital of isolation, blaAmpC, PFGE-type and
correlation with ST, phylogenetic group and cluster are given for each strain. Isolates clustered by PFGE proﬁles with ‡85% similarity are indi-
cated [black vertical line using the band-based DICE similarity coefﬁcient and the unweighted pairs geometric matched analysis (UPGMA) den-
drogram with position tolerance of 1.0% for optimization and 1.0% for band comparison]. A total of 30 single types were identiﬁed and three
clustered types of genetically related strains are labelled C1-C3. PFGE patterns were not obtained from one isolate (CMY-2 producing K26-21,
ST31) as a result of DNA autodigestion (Table 1).
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remnants. The location of blaCMY with replicons I1, FII and
A/C was conﬁrmed by co-hybridization with the respective
probes in all isolates. Multiple-plasmid isolates (n = 20)
included ten different replicons with up to six replicon types
in single isolates: A/C-FII-FIB-Y (n = 4), I1-FII-FIB (n = 3),
FII-FIB-Y-K (n = 2), I1-FII-FIB-Y (n = 1), A/C-FII-FIA-FIB-Y
(n = 1), A/C-FII-FIA-FIB-Y-P (n = 1), I1-FIA-FIB-Y (n = 1), I1-
FII-FIA-FIB (n = 1), I1-FII-FIA-FIB-P (n = 1), I1-FII-FIA-FIB-Y
(n = 1), I1-FII-FIB-N-K (n = 1), I1-FII-FIB-P (n = 1), I1-FII-FIB-
P-K-B/O (n = 1) and Y-K-B/O (n = 1). Co-hybridization of
blaCMY and replicons I1, A/C and FII probes conﬁrmed
blaCMY-linked replicons; I1 (n = 6), A/C-FII (n = 3), I1-FII
(n = 2), A/C (n = 2), FII (n = 2) and none of the aforemen-
tioned replicons (n = 5) (Table 1).
Transferability of blaCMY
Transfer of blaCMY was observed in six out of ten isolates.
Transfer frequencies ranged from 2.6 · 10)6 to 3.4 · 10)3/
donor cells. Transconjugants were conﬁrmed for blaCMY-2
(n = 5) and blaCMY-7 (n = 1) on both IncI1- and IncA/C-type
plasmids. Transconjugants of blaCMY-7 (IncI1) and blaCMY-2
(IncA/C) donors K2-67 and K5-41, respectively, co-trans-
ferred resistance to SXT (Table 1). Transfer was not
observed for one donor strain (K05-63) with a chromosom-
ally located blaCMY-2.
Discussion
We have carried out a broad molecular epidemiological
characterization of PABL-producing E. coli collected during
2003–2007 in a nationwide laboratory based study. For
2007, the Norwegian surveillance system for antimicrobial
resistance (NORM) calculated the prevalence of resistance
to cefotaxime and/or ceftazidime in blood culture E. coli iso-
lates to be 2.7% (n = 32) [21]. The same report veriﬁed
1.2% as ESBL producers and only 18 (1.5%) as non-ESBL iso-
lates. Given that most of the non-ESBL isolates have an
AmpC-phenotype and that only 14% of our nationwide
AmpC-phenotype strains were PABL positive, we infer that
PABL-producing E. coli are rarely encountered in Norway.
In our study, we observed a dominance of CMY-2 type
plasmid-mediated AmpC (92%), consistent with worldwide
observations [22]. Additionally, we identiﬁed a low presence
of DHA-1 enzyme (5%), which has mostly been reported
from Asia [23]. The CMY-2-producing isolates generally
expressed high mean MIC values against oxyimino-cephalo-
sporins (except cefepime). Compared with the AmpC-pheno-
type of PABL-PCR negative E. coli, the mean MICs against
oxyimino-cephalosporins were generally higher (data not
shown), but a large overlap existed between the two groups.
PFGE-analysis revealed that the majority of CMY-2-producing
isolates were genetically unrelated, and only three minor clus-
ters were observed. Moreover, most PABL-producing strains
were distributed temporally and geographically. Thus, the
occurrence of these strains in Norway seems to be sporadic.
BlaCMY-2 was seen on large multi-replicon IncI1 and IncA/
C plasmids often co-located with other F-replicons, e.g. FII
and/or FIA. Furthermore, IncI1 and IncA/C plasmids were
shown to be transferable, co-transferring SXT resistance
[24]. The linkage of blaCMY-2 to ISEcp1 has been documented
in numerous studies and three different truncated forms of
ISEcp1-like elements upstream have been identiﬁed [6]. The
linkage of ISEcp1 to blaCMY was established in 91% of the iso-
lates, as previously shown in Norwegian blaCMY E. coli iso-
lates [9], supporting the notion that ISEcp1 is the probable
mediator for mobilization and high-level expression of blaCMY
as observed for blaCTX-M [25].
The recently observed worldwide clonal dissemination of
E. coli ST131 producing CTX-M-15 encouraged us to investi-
gate PABLs at the strain level. Population analysis of the
CMY-2-producing PABL strains revealed that 16/35 (46%) of
the isolates were related to internationally disseminated
strains of STC 38, STC 448 and ST131. To our knowledge,
no MLST analysis of PABL-producing strains has previously
been described.
Present data from the MLST database show that strains
related to STC 38 consist of globally distributed uropatho-
genic and enteroaggregative E. coli isolates from Brazil, Ger-
many, India and Nigeria. Furthermore, ST38 strains have
recently been identiﬁed in Japan among CTX-M-producing
isolates [26]. Our STC 38-related strains (n = 7) belonged to
the phylogenetic group D and included the SLV ST788 iso-
lates of the PFGE C3. Furthermore, all ST788 isolates
(n = 4) and one ST38 isolate were identiﬁed with blaCMY-2
linked to an ISEcp1 element upstream. Interestingly, hybrid-
ization with blaCMY-2-speciﬁc probes identiﬁed a possible
chromosomal location in these ﬁve isolates, and a plasmid
location in the two remaining isolates. A possible chromo-
somal integration of blaCMY-2 in E. coli has previously been
suggested [9,24] and reported for Proteus mirabilis [27].
Strains submitted to the MLST database related to STC
448 are mostly pathogenic E. coli isolated from Germany,
Scotland, India, Thailand and Nigeria. Our STC 448-related
isolates were all ST448 with blaCMY-2 linked to an ISEcp1 ele-
ment upstream (n = 5). Three isolates were of phylogenetic
group B1 and two of group A. Two isolates clustered in
PFGE C2. Four isolates, including the C2 isolates, were also
shown to have a possible chromosomal location when
hybridized with a blaCMY-2 probe.
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Recently, ST131-related E. coli strains have been associ-
ated with the global dissemination of CTX-M-15 type ESBL
[28,29]. Furthermore, ST131 strains have been described as
the major extended spectrum cephalosporin-resistant uro-
pathogenic strains and plasmid-mediated quinolone resistance
strains in the UK [30,31] and ciproﬂoxacin-resistant strain in
eight European countries [32]. They have also been isolated
from the stools of healthy individuals in France [33]. Taken
together, these observations suggest that ST131 had a
worldwide dissemination even before the acquisition of ESBL
resistance determinants. In this study, a total of four isolates
were ST131. They were all CMY-2 producers belonging to
phylogenetic group B2 consistent with the documented
ST131 reports [34]. However, none of the PABL-producing
isolates were positive for blaCTX-M by consensus PCR. More-
over, the observations of low cefepime MICs in combination
with a lack of clavulanic acid synergy in ESBL Etests strongly
indicate that Norwegian PABL-producing E. coli strains are
not associated with ESBL production.
This study documents blaCMY-2 on large broad host-range
conjugative plasmids linked to multidrug resistant lineages of
E. coli across Norway; STCs 38, 448 and ST131. The pres-
ence of multidrug resistant ST131 strains requires special
attention and monitoring. These observations support long-
term persistence in colonized hosts which facilitates further
dissemination even in a country such as Norway with a rela-
tively low usage of antimicrobial agents.
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